A Rapid Review of Potential Drug Treatments for Children with COVID-19
Total Views: 254 | Total Downloads: 219
The paediatric population constitutes a much smaller proportion of COVID-19 patients and seems to be less severely affected. However, the massive numbers of COVID-19 infections mean that many children require treatment in hospital. In the concerted and wide-ranging effort to discover a safe and effective treatment for COVID-19, paediatric involvement is necessary. This review aims to identify leading potential drug treatments and vaccines for COVID-19 that are being investigated with children involved. Clinicaltrials.gov, WHO Trial Registry Platform (ICTRP) and RAPS COVID-19 vaccine tracker webportals were searched for clinical trials in phase 3 that involved children below 15 years of age. Any preliminary results released were searched online. The review found 25 phase 3 drug trials with paediatric participants and 2 vaccine trials. No preliminary findings were found. Remdesivir appears to be a leading candidate drug treatment and 2 vaccines candidates, inactivated nCoV-19 (Sinopharm) and ChAdOx1 (Oxford University), are recruiting children in large phase 3 trials. No treatments are currently licensed for COVID-19 but results from numerous trials are eagerly awaited.
How to Cite
Copyright (c) 2021 Khairun Nain Nor Aripin, Muhammad Yusoff Mohd Ramdzan, Jamil Aiman Mohd Baharudin
This work is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of this article will be vested to author(s) and granted the journal right of first publication with the work simultaneously licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license, unless otherwise stated.